BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

837 related articles for article (PubMed ID: 15243126)

  • 21. Mitogenic signaling of urokinase receptor-deficient kidney fibroblasts: actions of an alternative urokinase receptor and LDL receptor-related protein.
    Zhang G; Cai X; López-Guisa JM; Collins SJ; Eddy AA
    J Am Soc Nephrol; 2004 Aug; 15(8):2090-102. PubMed ID: 15284295
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression and localization of the urokinase-type plasminogen activator receptor (uPAR) in the human placenta.
    Nishida Y; Hayashi Y; Imai Y; Itoh H
    Kobe J Med Sci; 1998 Feb; 44(1):31-43. PubMed ID: 9846056
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tissue distribution of soluble and receptor-bound urokinase in human breast cancer using a panel of monoclonal antibodies.
    Carriero MV; Franco P; Del Vecchio S; Massa O; Botti G; D'Aiuto G; Stoppelli MP; Salvatore M
    Cancer Res; 1994 Oct; 54(20):5445-54. PubMed ID: 7923178
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Localization and significance of urokinase plasminogen activator and its receptor in placental tissue from intrauterine, ectopic and molar pregnancies.
    Floridon C; Nielsen O; Holund B; Sunde L; Westergaard JG; Thomsen SG; Teisner B
    Placenta; 1999 Nov; 20(8):711-21. PubMed ID: 10527826
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunohistochemical detection of uPA, uPAR, PAI-1, and maspin in ameloblastic tumors.
    Kumamoto H; Ooya K
    J Oral Pathol Med; 2007 Sep; 36(8):488-94. PubMed ID: 17686008
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Deflazacort modulates the fibrinolytic pattern and reduces uPA-dependent chemioinvasion and proliferation in rheumatoid arthritis synoviocytes.
    Del Rosso A; Cinelli M; Guiducci S; Pignone A; Fibbi G; Margheri F; Gabrielli A; Giacomelli R; Coppini A; Del Rosso M; Matucci Cerinic M
    Rheumatology (Oxford); 2005 Oct; 44(10):1255-62. PubMed ID: 15998634
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The urokinase plasminogen activator (uPA) system in uterine natural killer cells in the placental bed during early pregnancy.
    Naruse K; Lash GE; Bulmer JN; Innes BA; Otun HA; Searle RF; Robson SC
    Placenta; 2009 May; 30(5):398-404. PubMed ID: 19272641
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Plasminogen activators and plasminogen activator inhibitor type-1 in human endometrium].
    Chen GA; Feng Q; Zhang LZ; Liu YX
    Sheng Li Xue Bao; 1992 Oct; 44(5):502-9. PubMed ID: 1293766
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biological mechanisms underlying the clinical effects of mifepristone (RU 486) on the endometrium.
    Papp C; Schatz F; Krikun G; Hausknecht V; Lockwood CJ
    Early Pregnancy (Cherry Hill); 2000 Oct; 4(4):230-9. PubMed ID: 11742418
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression of plasminogen activator inhibitors type 1 and type 3 and urokinase plasminogen activator protein and mRNA in breast cancer.
    Castelló R; Landete JM; España F; Vázquez C; Fuster C; Almenar SM; Ramón LA; Radtke KP; Estellés A
    Thromb Res; 2007; 120(5):753-62. PubMed ID: 17258797
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of hypoxia and reoxygenation on the expression levels of the urokinase-type plasminogen activator, its inhibitor plasminogen activator inhibitor type-1 and the urokinase-type plasminogen activator receptor in human head and neck tumour cells.
    Sprague LD; Tomaso H; Mengele K; Schilling D; Bayer C; Stadler P; Schmitt M; Molls M
    Oncol Rep; 2007 May; 17(5):1259-68. PubMed ID: 17390074
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Regulated localization confers multiple functions on the protease urokinase plasminogen activator.
    Wells JM; Strickland S
    J Cell Physiol; 1997 May; 171(2):217-25. PubMed ID: 9130470
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Structure, function and expression on blood and bone marrow cells of the urokinase-type plasminogen activator receptor, uPAR.
    Plesner T; Behrendt N; Ploug M
    Stem Cells; 1997; 15(6):398-408. PubMed ID: 9402652
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Elevated urokinase-specific surface receptor expression is maintained through its interaction with urokinase plasminogen activator.
    Mahanivong C; Yu J; Huang S
    Mol Carcinog; 2007 Mar; 46(3):165-75. PubMed ID: 17186542
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: comparison to antigen quantification by ELISA.
    Biermann JC; Holzscheiter L; Kotzsch M; Luther T; Kiechle-Bahat M; Sweep FC; Span PN; Schmitt M; Magdolen V
    Int J Mol Med; 2008 Feb; 21(2):251-9. PubMed ID: 18204793
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression of urokinase-type plasminogen activator and its receptor is up-regulated during tendon healing.
    Xia W; de Bock C; Murrell GA; Wang Y
    J Orthop Res; 2003 Sep; 21(5):819-25. PubMed ID: 12919869
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In situ stromal expression of the urokinase/plasmin system correlates with epithelial dysplasia in colorectal adenomas.
    Sordat I; Chaubert P; Protiva P; Guillou L; Mazzucchelli L; Saraga E; Benhattar J; Trân-Thang C; Blum AL; Dorta G; Sordat B
    Am J Pathol; 1997 Jan; 150(1):283-95. PubMed ID: 9006343
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mutational analysis of the genes encoding urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in advanced ovarian cancer.
    Türkmen B; Schmitt M; Schmalfeldt B; Trommler P; Hell W; Creutzburg S; Graeff H; Magdolen V
    Electrophoresis; 1997 May; 18(5):686-9. PubMed ID: 9194591
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cyclo19,31[D-Cys19]-uPA19-31 is a potent competitive antagonist of the interaction of urokinase-type plasminogen activator with its receptor (CD87).
    Magdolen V; Bürgle M; de Prada NA; Schmiedeberg N; Riemer C; Schroeck F; Kellermann J; Degitz K; Wilhelm OG; Schmitt M; Kessler H
    Biol Chem; 2001 Aug; 382(8):1197-205. PubMed ID: 11592401
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: correlation with tumor associated macrophage and prognosis.
    Ohba K; Miyata Y; Kanda S; Koga S; Hayashi T; Kanetake H
    J Urol; 2005 Aug; 174(2):461-5. PubMed ID: 16006865
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 42.